Acquisition enhances capabilities in livestock productivity, disease prediction, and sustainability

Zoetis Inc. is doubling down on data-driven livestock innovation with a $160 million agreement to acquire the animal genomics business of Neogen Corporation, a move that underscores the growing role of genetics in shaping the future of animal health.

The acquisition, expected to close in the second half of 2026 subject to regulatory approvals, is designed to strengthen Zoetis’ position in Precision Animal Health—a rapidly evolving segment that combines genomics, diagnostics, and predictive analytics to deliver individualized care and improve productivity across livestock and companion animals.

Building a Genomics-Led Platform

Neogen’s genomics unit brings a global footprint, serving customers in more than 120 countries through laboratories in the U.S., Brazil, Australia, China, and the U.K., along with operations in Canada. The business is particularly strong in U.S. beef and dairy genomics, where genetic testing is increasingly central to herd improvement strategies.

Its platform integrates fixed array and sequencing technologies with software tools that enable producers to make data-driven decisions around breeding, disease resistance, and performance optimization.

By integrating these capabilities, Zoetis is positioning itself to offer deeper predictive insights—helping farmers anticipate health risks, enhance productivity, and improve sustainability outcomes.

The Rise of Precision Animal Health

The deal reflects a broader structural shift in animal agriculture. As producers face pressure to improve efficiency while reducing environmental impact, genomics is emerging as a critical lever—enabling more precise breeding, early disease detection, and targeted interventions.

For Zoetis, the acquisition extends beyond diagnostics into a more comprehensive, data-centric ecosystem where genetics, health management, and digital tools converge.

Strategic Fit and Global Scale

The addition of Neogen’s genomics business complements Zoetis’ existing portfolio of vaccines, medicines, and diagnostics, creating opportunities to integrate genetic insights directly into herd health programs.

The company is also expected to leverage the acquired capabilities to expand its reach in key livestock markets globally, while enhancing value for producers through more personalized and predictive solutions.

Integration and Outlook

Zoetis has indicated that it will focus on a seamless integration process, maintaining continuity for customers and employees while building on Neogen’s established genomics expertise.

The deal is subject to customary closing conditions and the satisfaction of regulatory requirements, and Zoetis expects to complete the acquisition in the second half of calendar year 2026.